WEST
SACRAMENTO, Calif., Nov. 25,
2024 /PRNewswire/ -- Gemini Bioproducts, LLC
("GeminiBio"), a leading supplier of cell culture reagents and
process liquids, and a portfolio company of BelHealth Investment
Partners, LLC ("BelHealth"), a Florida-based healthcare private equity firm,
today announced the acquisition of selected fetal bovine serum
(FBS) product rights and inventory from Bio-Techne (NASDAQ:
TECH).
GeminiBio has a 39-year history of supporting FBS customers.
With this agreement, GeminiBio builds on these capabilities, by
securing the manufacturing and global sales rights for Bio-Techne's
R&D Systems fetal bovine serum (FBS) product brands, Optima,
Premium Select, and Premium. Following Bio-Techne's decision to
discontinue their FBS products, GeminiBio worked closely with the
company to create a seamless transition plan, ensuring continuous
access to these high-quality FBS products for existing
customers.
"While Bio-Techne decided to discontinue the FBS product line,
we have worked diligently to ensure continuity of supply for our
customers. We are pleased that these important cell culture
products will remain available through GeminiBio," said
Will Geist, President of
Bio-Techne's Protein Science Segment. "We have significant
experience with GeminiBio's cGMP manufacturing capabilities and
level of quality, and believe they are well-positioned to support
the ongoing availability of these FBS product brands to our
customers."
"We are fully committed to maintaining ongoing market access to
these products," said Brian Parker,
Chief Executive Officer of GeminiBio. "Customers can expect the
same high-quality standards, reliable supply chain, product names,
specifications, and part numbers. With the addition of the Optima,
Premium Select, and Premium product brands, GeminiBio strengthens
its market position, providing customers with expanded options and
enhanced supply chain security."
The effective date for the transition of these products to
GeminiBio is December 3, 2024. All
orders or inquiries specific to Optima, Premium Select, and Premium
FBS should be directed to info@geminibio.com on or after
December 3, 2024.
Over the past two years, GeminiBio has expanded its cGMP
manufacturing footprint with two separate facilities in
West Sacramento, CA – one
dedicated to animal origin (AO) product manufacturing, and the
other focused on animal origin-free (AOF) product manufacturing.
With these manufacturing capabilities, GeminiBio supports a diverse
life science and biotech customer base, including early-stage
researchers, as well as clinical and commercial stage
biotechs. "GeminiBio is excited to integrate these new
product brands – and support the ongoing success of new customers"
said Mr. Parker, "and importantly, this acquisition increases the
company's size and scale, positioning us to better accomplish our
mission of helping improve customer workflows, and ultimately,
accelerate the development of life-enhancing biotherapeutics."
About BelHealth Investment Partners
BelHealth Investment Partners, based in Fort Lauderdale, Florida, is a healthcare
private equity firm focused on lower middle market companies.
BelHealth has a unique combination of investing, executive
management, and entrepreneurial experience. BelHealth acquires
majority positions in entrepreneur-owned companies that it believes
will benefit from its extensive operating and private equity
investment expertise. BelHealth is investing from its current
$350 million fund. For more
information, visit www.belhealth.com
About GeminiBio
Founded in 1985, GeminiBio serves the global biotechnology
industry, from basic research to commercial production, with a
focus on helping customers accelerate the development of
life-enhancing biotherapeutics by streamlining and improving their
cell culture and process liquid manufacturing workflows. The
company's products are organized into two core verticals – Cell
Culture Solutions and Process Liquid Solutions. Located in
West Sacramento, California,
GeminiBio has 57,000 square feet of cGMP manufacturing space,
segregated between animal origin-free and animal component
manufacturing. GeminiBio is an ISO 13485:2016 certified,
FDA-registered Class 1 Medical Device Manufacturer, aligned with 21
CFR Part 820. For more information, visit
www.geminibio.com.
Contact:
GeminiBio: Kim Thompson,
kthompson@geminibio.com
GeminiBio: Brian Parker,
bparker@geminibio.com
BelHealth Investment Partners: Inder
Tallur, itallur@belhealth.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/gemini-bioproducts-llc-acquires-selected-fetal-bovine-serum-fbs-product-rights-and-inventory-from-bio-techne-302314934.html
SOURCE Gemini Bioproducts, LLC